Sanofi-Aventis (SNY) Says Multaq Study Shows 24% Cut in Cardio Hospitalization/Death -Bloomberg
More News related to SNY
- National Transitions of Care Coalition Conducted Information Exchange on the Issue of Transitions of Care
- SAFE-BioPharma Announces Fast, Innovative Identity Proofing Procedure
- Olympic Gymnasts Promote Cancer Awareness Oct. 2 at the Steeplechase Cancer Center
- RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
- Ben Vereen, Tony Award-Winning Actor, Strives to Raise Awareness of Diabetes and Treatment
More News related to Corporate News
- PeopleSupport (PSPT) Receives Request from Essar Services to Schedule Closing of Merger
- Frequency Electronics (FEIM) Receives $4M Contract to Provide Satellite Payload Products for Military Space Program
- Tetra Tech (TTEK) Wins $25.6M Contract to "Green" Ports in LA and Long Beach
- Pep Boys (PBY) Announces Reorganization of Field Structure: Decreases Divisions from 8 to 6
- Converted Organics (COIN) Announces Initial Sale of 66 Tons of Organic Fertilizer to Matosantos
Bloomberg is reporting that Sanofi-Aventis (NYSE: SNY) said Multaq results show statistical significance: Multaq reduced cardio hospitalization/death by 24%.
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
